XPAR
AMPLI
Market cap349mUSD
Oct 09, Last price
6.25EUR
Name
Amplitude Surgical SA
Chart & Performance
P/E
196.23
P/S
2.83
EPS
0.03
Div Yield, %
—
Shrs. gr., 5y
0.07%
Rev. gr., 5y
0.67%
Revenues
106m
+5.81%
Net income
2m
-96.11%
CFO
4m
-50.06%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle. The company also provides AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and the E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, it offers instruments for fitting implants. The company sells its products through a network of distributors and agents in approximately 30 countries. It serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France.
IPO date
Jun 26, 2015
Employees
489
Domiciled in
FR
Incorporated in
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||